# Ivana Knezevic

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5478515/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 45 papers | 1,881 citations | 361413 20 h-index | 289244 40 g-index |
| 61 all docs | 61 docs citations | 61 times ranked | 3233 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe, The, 2022, 3, e235-e240. | 7.3 | 108 |
| 2 | WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June â€“ 2 July 2021. Biologicals, 2022, 76, 1-9. | 1.4 | 2 |
| 3 | Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. BioDrugs, 2022, 36, 359-371. | 4.6 | 14 |
| 4 | Regulatory challenges with biosimilars: an update from 20 countries. Annals of the New York Academy of Sciences, 2021, 1491, 42-59. | 3.8 | 20 |
| 5 | WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet, The, 2021, 397, 1347-1348. | 13.7 | 308 |
| 6 | A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells. Npj Vaccines, 2021, 6, 83. | 6.0 | 25 |
| 7 | Biosimilars â€“ status in July 2020 in 16 countries. GaBI Journal, 2021, 10, 4-32. | 0.3 | 3 |
| 8 | Removal of the innocuity test from The International Pharmacopoeia and WHO recommendations for vaccines and biological products. Biologicals, 2020, 66, 17-20. | 1.4 | 8 |
| 9 | WHO informal consultation on the guidelines for evaluation of the quality, safety, and efficacy of DNA vaccines, Geneva, Switzerland, December 2019. Npj Vaccines, 2020, 5, 52. | 6.0 | 3 |
| 10 | The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019. Biologicals, 2020, 65, 1-9. | 1.4 | 34 |
| 11 | 1st WHO International Standard antiserum to RSV: Availability and benefits for RSV vaccine development (Commentary on the collaborative study report published in the vaccine journal) Tj ETQq1 1 0.784314 rgBT /Overlock 10 | 4.8 | 2 |
| 12 | Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody. Npj Vaccines, 2019, 4, 42. | 6.0 | 13 |
| 13 | Prevalence of oncogenic Human papillomavirus and genetic diversity in the L1 gene of HPV16 HPV 18 HPV31 and HPV33 found in women from Vojvodina Province Serbia. Biologicals, 2019, 58, 57-63. | 1.4 | 16 |
| 14 | Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case study. Biologicals, 2019, 62, 8-15. | 1.4 | 6 |
| 15 | An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route. Vaccine, 2019, 37, A99-A106. | 3.8 | 30 |
| 16 | Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates. Vaccine, 2019, 37, 863-868. | 3.8 | 60 |
| 17 | Human challenge trials in vaccine development, Rockville, MD, USA, September 28â€“30, 2017. Biologicals, 2019, 61, 85-94. | 1.4 | 29 |
| 18 | Biosimilars. , 2018, , 345-358. | | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Report of the international conference on next generation sequencing for adventitious virus detection in biologicals. Biologicals, 2018, 55, 1-16. | 1.4 | 14 |
| 20 | The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infectious Diseases, The, 2018, 18, e295-e311. | 9.1 | 355 |
| 21 | Regulatory evaluation of biosimilars throughout their product life-cycle. Bulletin of the World Health Organization, 2018, 96, 281-285. | 3.3 | 20 |
| 22 | WHO standards for biotherapeutics, including biosimilars: an example of the evaluation of complex biological products. Annals of the New York Academy of Sciences, 2017, 1407, 5-16. | 3.8 | 16 |
| 23 | Scientific considerations for the regulatory evaluation of cell therapy products. Biologicals, 2017, 50, 20-26. | 1.4 | 43 |
| 24 | High-risk human papilloma virus genotypes in cervical carcinoma of Serbian women: Distribution and association with pathohistological findings. Biologicals, 2016, 44, 412-416. | 1.4 | 9 |
| 25 | Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines â€“ A review from a regulatory perspective. Biologicals, 2016, 44, 90-110. | 1.4 | 5 |
| 26 | Review of efficacy trials of HIV-1/AIDS vaccines and regulatory lessons learned. Biologicals, 2016, 44, 73-89. | 1.4 | 17 |
| 27 | Review of the current use and evaluation of cell substrates for producing biologicals in selected countries. Biologicals, 2015, 43, 153-157. | 1.4 | 0 |
| 28 | WHO consultation on clinical evaluation of vaccines, 17â€“18 July 2014, WHO Headquarters, Geneva, Switzerland. Vaccine, 2015, 33, 1999-2003. | 3.8 | 0 |
| 29 | Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility. Biologicals, 2015, 43, 298-306. | 1.4 | 114 |
| 30 | Immunogenicity assessment of monoclonal antibody products: A simulated case study correlating antibody induction with clinical outcomes. Biologicals, 2015, 43, 307-317. | 1.4 | 17 |
| 31 | Case studies on clinical evaluation of biosimilar monoclonal antibody: Scientific considerations for regulatory approval. Biologicals, 2015, 43, 1-10. | 1.4 | 18 |
| 32 | Animal cell substrates for the production of biologicals: An introduction to WHO documents. Biologicals, 2014, , 101090. | 1.4 | 0 |
| 33 | Adventitious agents in viral vaccines: Lessons learned from 4 case studies. Biologicals, 2014, 42, 223-236. | 1.4 | 45 |
| 34 | Working Group on quality, safety and efficacy of typhoid Vi capsular polysaccharide conjugate, vaccines, Jeju, Republic of Korea, 5â€“7 September 2012. Vaccine, 2013, 31, 4466-4469. | 3.8 | 11 |
| 35 | International regulatory requirements for vaccine safety and potency testing: a WHO perspective&. Procedia in Vaccinology, 2011, 5, 164-170. | 0.4 | 13 |
| 36 | Evaluation of similar biotherapeutic products (SBPs): Scientific principles and their implementation. Biologicals, 2011, 39, 256-261. | 1.4 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24â€“26 August, 2010. Biologicals, 2011, 39, 349-357. | 1.4 | 11 |
| 38 | Biosimilars â€“ Global issues, national solutions. Biologicals, 2011, 39, 252-255. | 1.4 | 28 |
| 39 | Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Biologicals, 2010, 38, 162-169. | 1.4 | 39 |
| 40 | WHO Informal Consultation on standardization and evaluation of BCG vaccines Geneva, Switzerland 22â€“23 September 2009. Vaccine, 2010, 28, 6945-6950. | 3.8 | 30 |
| 41 | Stability evaluation of vaccines: WHO approach. Biologicals, 2009, 37, 357-359. | 1.4 | 16 |
| 42 | Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine. Vaccine, 2008, 26, 4754-4757. | 3.8 | 14 |
| 43 | Report on a WHO consultation on the characterisation of BCG vaccines, WHO, Geneva, Switzerland 8â€“9 Dec 2004. Vaccine, 2005, 23, 5700-5704. | 3.8 | 12 |
| 44 | Thiomersal in vaccines: a regulatory perspective. Vaccine, 2004, 22, 1836-1841. | 3.8 | 19 |
| 45 | Vaccine qualityâ€”can a single standard be defined?. Vaccine, 2002, 20, 1000-1003. | 3.8 | 14 |